FOXO1 and lymphoma: In particular, a significant fraction of B cell–originated lymphomas, including approximately 12% of Burkitt lymphomas (BLs) and approximately 9% of diffuse large B cell lymphomas (DLBCLs), carry activating FOXO1 missense mutations (29, 30), suggesting that FOXO1 can act as a tumor suppressor or a lineage-survival oncogene in a strictly context-dependent manner.